- Home
- DBI vs FATE Comparison
DBI vs FATE Comparison
Compare DBI & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBI
- FATE
- Stock Information
- Founded
- DBI 1991
- FATE 2007
- Country
- DBI United States
- FATE United States
- Employees
- DBI N/A
- FATE N/A
- Industry
- DBI Clothing/Shoe/Accessory Stores
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DBI Consumer Discretionary
- FATE Health Care
- Exchange
- DBI Nasdaq
- FATE Nasdaq
- Market Cap
- DBI 161.1M
- FATE 129.5M
- IPO Year
- DBI 1991
- FATE 2013
- Fundamental
- Price
- DBI $2.87
- FATE $1.14
- Analyst Decision
- DBI Hold
- FATE Hold
- Analyst Count
- DBI 2
- FATE 7
- Target Price
- DBI $3.50
- FATE $3.83
- AVG Volume (30 Days)
- DBI 1.2M
- FATE 1.4M
- Earning Date
- DBI 09-10-2025
- FATE 08-12-2025
- Dividend Yield
- DBI 7.02%
- FATE N/A
- EPS Growth
- DBI N/A
- FATE N/A
- EPS
- DBI N/A
- FATE N/A
- Revenue
- DBI $2,949,575,000.00
- FATE $13,335,000.00
- Revenue This Year
- DBI N/A
- FATE N/A
- Revenue Next Year
- DBI $2.45
- FATE N/A
- P/E Ratio
- DBI N/A
- FATE N/A
- Revenue Growth
- DBI N/A
- FATE 105.85
- 52 Week Low
- DBI $2.18
- FATE $0.66
- 52 Week High
- DBI $8.45
- FATE $5.75
- Technical
- Relative Strength Index (RSI)
- DBI 45.82
- FATE 45.71
- Support Level
- DBI $2.67
- FATE $1.19
- Resistance Level
- DBI $3.41
- FATE $1.35
- Average True Range (ATR)
- DBI 0.21
- FATE 0.08
- MACD
- DBI 0.01
- FATE 0.01
- Stochastic Oscillator
- DBI 23.81
- FATE 16.00
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.